Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 69% of modeled bridge. Strengths: Occupancy Rate, Commercial Payer %. Risks: Revenue per Bed, Net-to-Gross Ratio. Risk-adjusted uplift: $0.4M (vs $0.6M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $232K | $232K | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $223K | $8K | $231K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $36K | $105K | $141K | $444K | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $10K | $10K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 55.9% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $58K | $116K | $174K | $232K | $232K | $232K | $232K |
| Denial Rate Reduction | $0 | $58K | $116K | $173K | $231K | $231K | $231K | $231K |
| A/R Days Reduction | $0 | $47K | $94K | $141K | $141K | $141K | $141K | $141K |
| Clean Claim Rate | $0 | $5K | $10K | $10K | $10K | $10K | $10K | $10K |
| Cumulative | $0 | $168K | $335K | $498K | $614K | $614K | $614K | $614K |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $614K is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 71% / 14.6x | 75% / 16.6x | 79% / 18.6x | 81% / 19.6x | 83% / 20.6x |
| 9.0x | 66% / 12.6x | 70% / 14.4x | 74% / 16.1x | 76% / 17.0x | 78% / 17.9x |
| 10.0x | 62% / 11.0x | 66% / 12.6x | 70% / 14.2x | 72% / 15.0x | 74% / 15.8x |
| 11.0x | 58% / 9.7x | 62% / 11.2x | 66% / 12.6x | 68% / 13.3x | 70% / 14.1x |
| 12.0x | 54% / 8.7x | 58% / 10.0x | 62% / 11.3x | 64% / 12.0x | 66% / 12.6x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 43% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 3.7x, adding 4.8 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $479K | — | $479K | 4.1% |
| Year 1 | $493K | +$409K | $902K | 7.8% |
| Year 2 | $508K | +$614K | $1.1M | 9.7% |
| Year 3 | $523K | +$614K | $1.1M | 9.8% |
| Year 4 | $539K | +$614K | $1.2M | 9.9% |
| Year 5 | $555K | +$614K | $1.2M | 10.1% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $116K | $174K | $232K | $278K |
| Denial Rate Reductio | $116K | $173K | $231K | $278K |
| A/R Days Reduction | $70K | $106K | $141K | $169K |
| Clean Claim Rate | $5K | $7K | $10K | $12K |
| Total | $307K | $460K | $614K | $736K |
Peer Context — Where This Hospital Sits
Key metrics vs 135 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 4.1% | -20.0% | -3.1% | 5.1% | P71 |
| Net-to-Gross | 66.1% | 31.7% | 43.3% | 55.9% | P87 |
| Occupancy | 62.7% | 21.5% | 48.4% | 69.5% | P67 |
| Rev/Bed | $362K | $280K | $459K | $815K | P39 |
| Exp/Bed | $347K | $269K | $442K | $963K | P39 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.